




Enabling UK companies to do research on UK samples

UK Biobanking presentation on the SME perspective




The Medicines Discovery Catapult




What is a Catapult?

- UK Government through its Innovation agency Innovate UK has established Catapults
 - to promote success of key industries
- Newest is Medicines Discovery
- An opportunity to reinvigorate UK's drug discovery industry
 - Help drug discovery, and new technology, businesses to grow
 - Join up the sector to do more, together
 - Expertise, facilities, partnership



How we do it





- Cell Biology
- Biomarker identification
- Diagnostics R&D
- Technologists
- Safety Scientists
- Bioanalytics
- Cheminformatics
- Bioinformatics
- In silico Intelligence
- Cloud infrastructures
- Workflow processing
- Software development
- Sample and Data access team
- Virtual R&D experts

UK Diagnostic interviews: results on samples access






More than 80% of companies had an issue accessing samples





The difficulty accessing UK samples means most companies buy in samples from abroad






Companies buying in non-UK samplesCompanies finding other solutions

Procurement was the most common issue faced by respondents dealing with UK sample sources










Action was called for in access to path samples, tissue registry, and other areas

Recommendations for MDC action





Summary of MDC proposed response

- MDC should support companies looking to work with UK biobanks
- Collaboration with CRC TDCC
 - –Market TDCC to companies
 - -Support biobank sign-up to TDCC, track inclusion & data completion
 - -Include commercial activity, user recommendations on registry
- Brokerage work
 - -Brokerage work between RTBs and users to support transactions
 - Develop and share guidance & templates for commercial sample transactions
- -Support initiatives allowing real-time sample identification, consent and